Home > News > Elan Licenses Its NanoCrystal Technology to Roche
April 21st, 2004
Elan Licenses Its NanoCrystal Technology to Roche
Abstract:
Elan Pharma International Ltd. today announced an agreement to license its proprietary NanoCrystal(TM) technology to Roche. NanoCrystal technology can improve the bioavailability of drugs by transforming them into nanometer-sized particles that can be used to create more effective and convenient dosage forms such as tablets, capsules, liquids, and powders. The license agreement will provide Roche with access to NanoCrystal technology and the rights to apply the technology to a drug candidate currently in clinical development.
Source:
Businesswire
Bookmark:
Nanomedicine
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Patents/IP/Tech Transfer/Licensing
Nanoparticle Opens the Door to Clean-Energy Alternatives June 14th, 2013
DRYWIRED™ Receives MILITARY-STANDARD Certifications from QUANTA LABORATORIES for Its Latest Protective Nano-Coating Technology June 5th, 2013
Apple patents point to slimmer battery tech June 1st, 2013
Patent for Coaxial Nanofibre Production: Scientists from Contipro have patented new jet for effective coaxial nanofibers production May 31st, 2013